The ATR Inhibitor Ceralasertib Potentiates Cancer Checkpoint Immunotherapy by Regulating the Tumor Microenvironment

Researchers showed that modeling of intermittent ceralasertib treatment in mouse tumor models revealed CD8+ T-cell dependent antitumor activity, which was separate from the effects on tumor cells.